Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer (NASDAQ: SEER) reported its Q1 2025 financial results, achieving revenue of $4.2 million, a 37% increase from $3.1 million in Q1 2024. The growth was primarily driven by higher product and service revenue. Product revenue reached $2.9 million, while service revenue was $1.2 million. The company reported a gross margin of 49% and a net loss of $19.9 million, improved from $20.7 million in the prior year.
Operating expenses decreased 14% to $22.8 million, including $4.5 million in stock-based compensation. Seer ended Q1 with approximately $285 million in cash and investments. The company secured a significant contract for a 10,000-sample study and maintained its full-year 2025 revenue guidance of $17-18 million, representing 24% growth at the midpoint over 2024.
Seer Inc (Nasdaq: SEER), a life sciences company focused on proteomics platform commercialization, has scheduled its first quarter 2025 financial results announcement for May 13, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section at investor.seer.bio, where a replay will also be available after the event.
Seer (Nasdaq: SEER) reported Q4 and full year 2024 financial results. Q4 revenue was $4.0M, down 10% YoY, while full-year revenue reached $14.2M, a 15% decrease from 2023. The company shipped 10 instruments in 2024, bringing total installations to 72.
Q4 gross profit was $2.0M with 51% margin, while operating expenses increased 5% to $25.5M. Net loss widened to $21.7M in Q4 2024 from $17.8M in Q4 2023. For the full year, net loss was $86.6M compared to $86.3M in 2023.
Notable developments include a new cell lysis proteomics application for the Proteograph XT workflow and a share repurchase of 6.5M shares at $1.82/share, reducing outstanding shares by 10%. The company ended 2024 with $300M in cash and investments. For 2025, Seer projects revenue of $17-18M, representing 24% growth at midpoint.
Seer (Nasdaq: SEER), a pioneering life sciences company focused on proteomics platform commercialization, has announced its participation in the TD Cowen 45th Annual Healthcare Conference in Boston, MA.
The company's management team will engage in a fireside chat scheduled for Tuesday, March 4th at 11:50 a.m. Eastern Time (8:50 a.m. Pacific Time). Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. An archived replay will be made available on the company's website after the conference concludes.
Seer Inc (Nasdaq: SEER) announced its participation in the 21st Annual US HUPO Conference in Philadelphia from February 22-26, 2025. The company will showcase new findings and host a seminar featuring groundbreaking research in cancer therapy using their Proteograph™ Product Suite.
The seminar will highlight Dr. Jinjun Shi's research from Brigham and Women's Hospital and Harvard Medical School, focusing on a novel co-delivery therapeutic platform that simultaneously targets cancer vulnerabilities using siRNA while activating tumor suppressors with mRNA. The study specifically addresses prostate cancer, the second leading cause of cancer death among men in the US.
Seer recently introduced a new workflow for deep cellular proteome analysis, adding to their existing 10+ Proteograph protocols for various sample types. The conference will also feature presentations from Seer and collaborators on tissue biology, cardiometabolic dysfunction biomarkers, and mass spectrometry proteomics throughput advancements.
Seer (Nasdaq: SEER) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The life sciences company, which specializes in proteomics platform technology, will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section of Seer's website at investor.seer.bio, where an archived replay will also be available after the event.
Seer (Nasdaq: SEER), a pioneer in proteomics platform technology, has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. The company's management team will deliver a presentation and engage in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live presentation, an archived replay will be made available on the company's website after the conference concludes.
Seer (Nasdaq: SEER) has been ranked No. 57 on the 2024 Deloitte Technology Fast 500™, achieving a remarkable 2,440% revenue growth. The company attributes this growth to increased adoption of its Proteograph Product Suite and customer discoveries across neurodegenerative disease, cancer, and metabolic disease. Key achievements include launching a technology access center in Europe, platform usage on the SpaceX Inspiration4 mission, and establishing a co-marketing agreement with Thermo Fisher Scientific. This marks Seer's second consecutive appearance on the list, improving from their No. 5 ranking in 2023.
Seer (Nasdaq: SEER) has announced its participation in two upcoming investor conferences in November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 11th at 11:30 a.m. ET, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21st at 10:00 a.m. ET.
Both sessions will be available via live webcast on the Investor section of Seer's website at investor.seer.bio, with archived replays accessible after the events.
Seer (NASDAQ: SEER) reported Q3 2024 financial results with revenue of $4.0 million, a 3% decrease from the prior year. Product revenue was $3.1 million, while service revenue reached $847 thousand. The company posted a gross margin of 48% and a net loss of $21.3 million. Operating expenses decreased 6% to $26.3 million. Key developments include a co-marketing agreement with Thermo Fisher Scientific, multiple research presentations at HUPO World Congress, and a $10.0 million investment in PrognomiQ. The company maintains its 2024 revenue guidance of $13-15 million and ended the quarter with $312 million in cash and investments.